First molecules to reactivate RASG12V GTPase activity
Abstract Background Small-molecule compounds that even partially restore the GTPase activity of RASG12V can be used in anticancer therapy. Until now, attempts to obtain such compounds have failed. Compounds with this ability have been defined in our research. Methods The compounds were initially ide...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-01-01
|
| Series: | BMC Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12885-025-13580-8 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832571575731224576 |
|---|---|
| author | Aneta Wlodarczyk Cezary Treda Marcin Pacholczyk Adrianna Rutkowska Marta Wegierska Amelia Kierasinska-Kalka Katarzyna Wasiak Damian Ciunowicz Dagmara Grot Pawel Glowacki Ewelina Stoczynska-Fidelus Piotr Rieske |
| author_facet | Aneta Wlodarczyk Cezary Treda Marcin Pacholczyk Adrianna Rutkowska Marta Wegierska Amelia Kierasinska-Kalka Katarzyna Wasiak Damian Ciunowicz Dagmara Grot Pawel Glowacki Ewelina Stoczynska-Fidelus Piotr Rieske |
| author_sort | Aneta Wlodarczyk |
| collection | DOAJ |
| description | Abstract Background Small-molecule compounds that even partially restore the GTPase activity of RASG12V can be used in anticancer therapy. Until now, attempts to obtain such compounds have failed. Compounds with this ability have been defined in our research. Methods The compounds were initially identified through virtual screening, and their optimal binding conformation in the RAS SW-II pocket was determined using the flexible docking technique. Efficacy was verified based on the IC50 determination, GTPase activity, as well as the AKT and ERK phospho WB assays. Results The IC50 of the tested compounds was significantly lower against cells with the RASG12V mutation than against selected types of normal cells. The molecular mechanism of action of these compounds was proposed – minimization of the negative impact of the V12 sidechain on GTP hydrolysis of RASG12V. The work also indicates that the model of action of RAS mutants in cell lines is incomplete. The analysed cell line (SW-480) with RAS mutations does not always show increased ERK and AKT activity. Conclusions We have demonstrated molecules that partially restore the GTPase activity of RASG12V. Their mechanism of action is well explained based on current RAS mutant conformation and mechanistic models. These molecules inhibit the RAS-AKT pathway and show higher cytotoxicity against cancer cells with the RASG12V mutation (SW-480 cell line). However, SW-480 cells can switch into the subline proliferating independently of AKT phosphorylation and show partial resistance to the molecules described in this article. |
| format | Article |
| id | doaj-art-3b0f7d0cc5c944cab21293cc128ebaaf |
| institution | Kabale University |
| issn | 1471-2407 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Cancer |
| spelling | doaj-art-3b0f7d0cc5c944cab21293cc128ebaaf2025-02-02T12:28:39ZengBMCBMC Cancer1471-24072025-01-0125111210.1186/s12885-025-13580-8First molecules to reactivate RASG12V GTPase activityAneta Wlodarczyk0Cezary Treda1Marcin Pacholczyk2Adrianna Rutkowska3Marta Wegierska4Amelia Kierasinska-Kalka5Katarzyna Wasiak6Damian Ciunowicz7Dagmara Grot8Pawel Glowacki9Ewelina Stoczynska-Fidelus10Piotr Rieske11Department of Research and DevelopmentDepartment of Research and DevelopmentDepartment of Tumor Biology, Chair of Medical Biology, Medical University of LodzDepartment of Research and DevelopmentDepartment of Research and DevelopmentDepartment of Research and DevelopmentDepartment of Research and DevelopmentDepartment of Research and DevelopmentDepartment of Research and DevelopmentDepartment of Research and DevelopmentDepartment of Research and DevelopmentDepartment of Research and DevelopmentAbstract Background Small-molecule compounds that even partially restore the GTPase activity of RASG12V can be used in anticancer therapy. Until now, attempts to obtain such compounds have failed. Compounds with this ability have been defined in our research. Methods The compounds were initially identified through virtual screening, and their optimal binding conformation in the RAS SW-II pocket was determined using the flexible docking technique. Efficacy was verified based on the IC50 determination, GTPase activity, as well as the AKT and ERK phospho WB assays. Results The IC50 of the tested compounds was significantly lower against cells with the RASG12V mutation than against selected types of normal cells. The molecular mechanism of action of these compounds was proposed – minimization of the negative impact of the V12 sidechain on GTP hydrolysis of RASG12V. The work also indicates that the model of action of RAS mutants in cell lines is incomplete. The analysed cell line (SW-480) with RAS mutations does not always show increased ERK and AKT activity. Conclusions We have demonstrated molecules that partially restore the GTPase activity of RASG12V. Their mechanism of action is well explained based on current RAS mutant conformation and mechanistic models. These molecules inhibit the RAS-AKT pathway and show higher cytotoxicity against cancer cells with the RASG12V mutation (SW-480 cell line). However, SW-480 cells can switch into the subline proliferating independently of AKT phosphorylation and show partial resistance to the molecules described in this article.https://doi.org/10.1186/s12885-025-13580-8RASSmall moleculeGTPaseLung cancerColorectal cancerPancreatic cancer |
| spellingShingle | Aneta Wlodarczyk Cezary Treda Marcin Pacholczyk Adrianna Rutkowska Marta Wegierska Amelia Kierasinska-Kalka Katarzyna Wasiak Damian Ciunowicz Dagmara Grot Pawel Glowacki Ewelina Stoczynska-Fidelus Piotr Rieske First molecules to reactivate RASG12V GTPase activity BMC Cancer RAS Small molecule GTPase Lung cancer Colorectal cancer Pancreatic cancer |
| title | First molecules to reactivate RASG12V GTPase activity |
| title_full | First molecules to reactivate RASG12V GTPase activity |
| title_fullStr | First molecules to reactivate RASG12V GTPase activity |
| title_full_unstemmed | First molecules to reactivate RASG12V GTPase activity |
| title_short | First molecules to reactivate RASG12V GTPase activity |
| title_sort | first molecules to reactivate rasg12v gtpase activity |
| topic | RAS Small molecule GTPase Lung cancer Colorectal cancer Pancreatic cancer |
| url | https://doi.org/10.1186/s12885-025-13580-8 |
| work_keys_str_mv | AT anetawlodarczyk firstmoleculestoreactivaterasg12vgtpaseactivity AT cezarytreda firstmoleculestoreactivaterasg12vgtpaseactivity AT marcinpacholczyk firstmoleculestoreactivaterasg12vgtpaseactivity AT adriannarutkowska firstmoleculestoreactivaterasg12vgtpaseactivity AT martawegierska firstmoleculestoreactivaterasg12vgtpaseactivity AT ameliakierasinskakalka firstmoleculestoreactivaterasg12vgtpaseactivity AT katarzynawasiak firstmoleculestoreactivaterasg12vgtpaseactivity AT damianciunowicz firstmoleculestoreactivaterasg12vgtpaseactivity AT dagmaragrot firstmoleculestoreactivaterasg12vgtpaseactivity AT pawelglowacki firstmoleculestoreactivaterasg12vgtpaseactivity AT ewelinastoczynskafidelus firstmoleculestoreactivaterasg12vgtpaseactivity AT piotrrieske firstmoleculestoreactivaterasg12vgtpaseactivity |